Compare ArcelorMittal SA (MT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Neurocrine Biosciences Inc — how do they compare? ArcelorMittal SA trades at $64.27 (market cap $45.70B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: ArcelorMittal SA is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and ArcelorMittal SA pays a 0.98% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MT | NBIX | |
|---|---|---|
Market Cap | $45.70B | $14.36B |
Volume | 1,964,621 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $185.50 |
52-Week Low | $36.91 | $123.10 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | $55.27B | $14.37B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $64.18, up 2.98% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains solid fundamentals with a P/E of 25.76 and P/S of 0.75, though recent Q2 2026 earnings missed expectations. Revenue has declined from $79.8B in 2022 to $61.4B in 2025, while net income improved to $3.2B. Recent news highlights operational challenges in Ukraine with a $1B impairment charge, but strategic partnerships and European demand improvements provide offsetting positives.
The outlook remains cautiously optimistic with analyst consensus price target of $74.33 representing 16% upside potential. Key opportunities include expanding steel capacity and regionalization benefits, while risks involve ongoing Ukraine operations disruption, China demand weakness, and elevated capital expenditures. Institutional sentiment leans bullish with 52% buy ratings, though technical resistance near $62-63 may limit near-term gains.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
